|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500112697 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-18 15:09:57 |
|
注册时间: Date of Registration: |
2025-11-18 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于功能导向组织成分重建策略的嵌合皮瓣新型分类体系 |
|
Public title: |
A Novel Classification System for Chimeric Flaps Based on a Function-Oriented Tissue Composition Reconstruction Strategy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
游离股前外侧嵌合皮瓣的临床分类及应用(基于功能导向组织成分重建策略的嵌合皮瓣新型分类体系) |
|
Scientific title: |
Clinical Classification and Applications of Free Anterolateral Thigh Chimeric Flaps (A Novel Classification System for Chimeric Flaps Based on a Function-Oriented Tissue Composition Reconstruction Strategy) |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张演基 |
研究负责人: |
邓呈亮 |
|
Applicant: |
Zhang Yanji |
Study leader: |
Deng Chengliang |
|
申请注册联系人电话: Applicant telephone: |
+86 185 2450 7852 |
研究负责人电话:
Study leader's |
+86 150 8511 5296 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
754290854@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
cheliadeng@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国贵州省遵义市汇川区大连路149号 |
研究负责人通讯地址: |
中国贵州省遵义市汇川区大连路149号 |
|
Applicant address: |
No. 149, Dalian Road, Huachuan District, Zunyi, Guizhou, China |
Study leader's address: |
No. 149, Dalian Road, Huachuan District, Zunyi, Guizhou, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
遵义医科大学附属医院 |
||
|
Applicant's institution: |
Zunyi Medical University Affiliated Hospital |
||
|
研究负责人所在单位: |
遵义医科大学附属医院 |
||
|
Affiliation of the Leader: |
Zunyi Medical University Affiliated Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KLL-2025-034 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
遵义医科大学附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Affiliated Hospital of Zunyi Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-24 00:00:00 | ||
|
伦理委员会联系人: |
张演基 |
||
|
Contact Name of the ethic committee: |
Zhang Yanji |
||
|
伦理委员会联系地址: |
中国贵州省遵义市汇川区大连路149号 |
||
|
Contact Address of the ethic committee: |
No. 149, Dalian Road, Huachuan District, Zunyi, Guizhou, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 185 2450 7852 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
754290854@qq.com |
|
研究实施负责(组长)单位: |
遵义医科大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zunyi Medical University Affiliated Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国贵州省遵义市汇川区大连路149号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 149, Dalian Road, Huachuan District, Zunyi, Guizhou, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
省部共建协同创新中心项目[教科技厅 函(2020)39号] |
||||||||||||||||||||||
|
Source(s) of funding: |
Collaborative Innovation Center of Chinese Ministry of Education (No. 2020-39) |
||||||||||||||||||||||
|
研究疾病: |
复杂创面 |
||||||||||||||||||||||
|
Target disease: |
Complex wound |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
验证基于新型嵌合皮瓣分类方法的嵌合皮瓣在复杂组织缺损修复中的临床应用价值。评估新型分类法在优化手术设计、减少并发症、缩短住院时间等方面的优势。 |
||||||||||||||||||||||
|
Objectives of Study: |
To validate the clinical value of chimeric flaps guided by the novel classification system in the reconstruction of complex tissue defects. The study aims to evaluate the advantages of the new classification in optimizing surgical design, reducing complications, and shortening hospital stay. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄18-70岁,性别不限; 2.面临高能创伤或软组织肿瘤切除后复杂组织缺损的患者; 3.需采用嵌合皮瓣修复的患者; 4.签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Age between 18 and 70 years, regardless of sex; 2.Patients with complex tissue defects resulting from high-energy trauma or soft tissue tumor resection; 3.Patients requiring reconstruction with a free anterolateral thigh chimeric flap; 4.Provision of written informed consent. |
||||||||||||||||||||||
|
排除标准: |
1.合并严重基础疾病(如心功能III级以上、肾功能衰竭等); 2.血管病变或血供条件严重受限的患者; 3.无法配合围手术期管理的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients with severe underlying diseases (e.g., cardiac function class III or above, renal failure); 2.Patients with vascular disorders or severely compromised blood supply; 3.Patients unable to comply with perioperative management. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-04-25 00:00:00至 To 2027-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-05-23 00:00:00 至 To 2025-08-20 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究原始数据将通过 ResMan临床研究公共管理平台(http://www.medresman.org/) 进行共享。在试验结束后 6个月内 上传经脱敏处理的完整研究数据集(包括受试者一般人口学特征、手术方案、术后随访指标等),去除所有可识别受试者身份的信息。合格研究者可通过平台提出申请,经项目负责人审核后方可获取相关数据。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data of this study will be shared through the ResMan Clinical Research Public Management Platform (http://www.medresman.org/). Within 6 months after the completion of the trial, the de-identified complete research data set (including the general demographic characteristics of the subjects, surgical plans, postoperative follow-up indicators, etc.) will be uploaded. All information that can identify the identity of the subjects will be removed. Qualified researchers can submit applications through the platform, and after being reviewed by the project leader, they will be granted access to the relevant data. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |